Welcome to our dedicated page for Vireo Growth SEC filings (Ticker: VREOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vireo Growth Inc. (VREOF) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, along with AI-powered summaries that help explain complex documents. Vireo is a British Columbia corporation with principal offices in Minneapolis, Minnesota, and it files current and periodic reports as an emerging growth company under the Securities Exchange Act.
Investors researching VREOF can use this page to review Form 8-K filings that describe material events such as mergers, asset purchases, restructurings, and financing transactions. For example, Vireo has filed multiple Form 8-K reports detailing its Agreement and Plan of Merger with Eaze Inc., its Asset Purchase Agreement to acquire Colorado dispensary assets and properties from PharmaCann Inc., and its Convertible Note Secondary Sale and Purchase Agreements related to Schwazze’s 13% Senior Secured Convertible Notes. Other 8-K filings outline the restructuring support agreement with Schwazze, the outcome of a public disposition of collateral, and the planned transfer of assets to a new entity to be majority-owned by Vireo.
Additional 8-Ks cover topics such as the acquisition of additional Schwazze notes, the resolution of litigation with Verano Holdings Corp., and the release of quarterly financial results. These filings often include detailed descriptions of consideration paid in subordinate voting shares, lock-up arrangements, security interests, and conditions precedent, as well as extensive forward-looking statement disclosures and references to risk factors in the company’s Form 10-K and Form 10-Q reports.
On Stock Titan, AI-generated insights can help readers quickly identify the key terms, conditions, and implications of each filing, from unregistered sales of equity securities to restructuring milestones and regulatory approval requirements. Users can also track how Vireo reports non-GAAP metrics, capital structure changes, and major transactions over time through its SEC submissions, while the platform’s real-time updates ensure new filings from EDGAR are incorporated as they are made available.
Vireo Growth Inc. director Victor E. Mancebo received equity-based compensation awards on May 15, 2026. He was granted 80,000 restricted stock units and a separate grant of 96,859 restricted stock units, each RSU representing a contingent right to one subordinate voting share. He also received stock options over 95,310 subordinate voting shares and another grant of options over 115,506 shares with a conversion price of $0.424 per share. According to the vesting schedules, one-third of each award vests on the grant date, one-third on March 31, 2027, and the remaining one-third on March 31, 2028. Vested RSUs settle in cash, subordinate voting shares, or a combination of both after vesting.
Vireo Growth Inc. director Hussey Ross Michael reported equity-based compensation grants on May 15, 2026. He received 80,000 restricted stock units and a separate grant of 96,859 restricted stock units, each tied to one subordinate voting share per unit.
He also received stock options over 95,310 subordinate voting shares and another option grant over 115,506 shares, with an exercise price of 0.424 per share and expiration on May 14, 2036. The footnotes state that both RSUs and options vest in three equal annual portions, beginning on the grant date and continuing through March 31, 2028, with RSUs settling in cash, shares, or a mix after vesting.
Vireo Growth Inc. director Judd Theodore Nordquist reported equity compensation awards consisting of restricted stock units and stock options tied to subordinate voting shares. On May 15, 2026, he received multiple grants that increase his potential future ownership if vesting conditions are met.
The awards include restricted stock units that each represent a contingent right to receive one subordinate voting share, plus stock options with an exercise price of $0.424 per share. Both RSUs and options vest in roughly one-third increments on the grant date, on March 31, 2027, and on March 31, 2028, with options expiring on May 14, 2036.
Vireo Growth Inc. Chief Accounting Officer Joseph Duxbury reported compensation-related equity activity on May 15, 2026. 133,333 restricted stock units vested and were exercised into an equal number of subordinate voting shares. Of these, 40,799 shares were withheld to cover tax obligations, leaving 95,534 shares owned directly afterward. On the same date, Duxbury also received a new grant of 133,333 restricted stock units, each representing a right to one subordinate voting share.
Vireo Growth Inc. general counsel and corporate secretary Sean Michael Apfelbaum exercised and received equity awards tied to restricted stock units. He acquired 133,333 subordinate voting shares through RSU conversion and received a new grant of 133,333 RSUs, each representing one subordinate voting share. On the same date, 39,067 shares were disposed of to satisfy tax withholding obligations upon vesting, leaving him with 232,121 subordinate voting shares held directly.
Vireo Growth Inc. reported much larger operations for the quarter ended March 31, 2026, driven by multiple acquisitions and a major asset purchase. Revenue rose to $106.2M from $24.5M a year earlier, with retail sales of $89.9M and wholesale of $16.3M.
Despite a higher gross profit of $59.3M, the company posted a net loss of $20.3M, compared with a $6.5M loss in 2025, mainly due to higher operating costs, transaction expenses, stock-based pay, and income taxes. Total assets increased to $928.8M, total liabilities to $634.7M, and cash plus restricted cash to $137.8M. Vireo completed or integrated several cannabis deals (Wholesome, Proper, Deep Roots, Vireo Health of Rocky Mountain/Schwazze) and added goodwill and licenses, while assuming new long-term and high‑coupon debt and lease obligations.
Vireo Growth Inc. reported strong expansion for the quarter ended March 31, 2026, driven largely by acquisitions. GAAP revenue reached $106.2 million, up 333.5% year-over-year, while GAAP gross profit was $59.3 million with a 55.8% margin. Adjusted EBITDA rose to $32.7 million, a 30.8% margin, compared with $6.6 million a year earlier.
Despite growth, the Company recorded a net loss of $20.3 million, similar per-share loss of $0.02 but on a much larger share base. Vireo ended the quarter with $137.8 million in cash and total current assets of $258.3 million versus current liabilities of $215.8 million.
The quarter and subsequent period included major M&A activity: closing the Schwazze acquisition and PharmaCann management agreement, completing the Eaze and Hawthorne deals, and signing a definitive agreement to acquire FLUENT plus a California retail joint venture with Glass House Brands. Vireo also highlighted the U.S. Department of Justice’s move to reclassify certain cannabis products to Schedule III and is evaluating potential operational and tax impacts.
Vireo Growth Inc. plans to acquire all outstanding shares of FLUENT Corp. in an all-stock transaction under a court-approved plan of arrangement. Each FLUENT share will be exchanged for 0.0705359 of a Vireo subordinate voting share, subject to standard anti-dilution adjustments.
Vireo expects, subject to regulatory approvals, to deepen its Florida presence to approximately 74 stores and about 144,000 square feet of combined cultivation and production canopy. The deal is conditioned on FLUENT shareholder and court approvals, a US$30 million debt-for-equity equitization, limited dissent, and other regulatory and financing milestones, with closing targeted for the fourth quarter of 2026.
Vireo Growth Inc. has filed a preliminary Form S-3 prospectus to register up to 3,097,390 Subordinate Voting Shares for resale by selling securityholders. The shares were issued in connection with Convertible Note Secondary Sale and Purchase Agreements related to Schwazze notes and were issued at a deemed price of $0.54 per share. The company will not receive proceeds from resales; the Selling Securityholders will receive proceeds. Shares outstanding were 1,360,581,362 as of April 21, 2026.